Health knowledge made personal
Join this community!
› Share page:
Search posts:

Acorda Therapeutics Submits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sc

Posted Nov 17 2009 10:20pm

New Drug Application (NDA) Submitted for Fampridine-SR ( 4-aminopyridine [4AP] )

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb 2, 2009 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) on January 30, 2009 for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS). The Company expects that the NDA filing, if accepted, will be subject to standard review, which would provide a target for the FDA to complete its review within ten months from receipt of the submission.

» Read More

Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
Post a comment
Write a comment:

Related Searches